154 research outputs found
All-particle cosmic ray energy spectrum measured with 26 IceTop stations
We report on a measurement of the cosmic ray energy spectrum with the IceTop
air shower array, the surface component of the IceCube Neutrino Observatory at
the South Pole. The data used in this analysis were taken between June and
October, 2007, with 26 surface stations operational at that time, corresponding
to about one third of the final array. The fiducial area used in this analysis
was 0.122 km^2. The analysis investigated the energy spectrum from 1 to 100 PeV
measured for three different zenith angle ranges between 0{\deg} and 46{\deg}.
Because of the isotropy of cosmic rays in this energy range the spectra from
all zenith angle intervals have to agree. The cosmic-ray energy spectrum was
determined under different assumptions on the primary mass composition. Good
agreement of spectra in the three zenith angle ranges was found for the
assumption of pure proton and a simple two-component model. For zenith angles
{\theta} < 30{\deg}, where the mass dependence is smallest, the knee in the
cosmic ray energy spectrum was observed between 3.5 and 4.32 PeV, depending on
composition assumption. Spectral indices above the knee range from -3.08 to
-3.11 depending on primary mass composition assumption. Moreover, an indication
of a flattening of the spectrum above 22 PeV were observed.Comment: 38 pages, 17 figure
An improved method for measuring muon energy using the truncated mean of dE/dx
The measurement of muon energy is critical for many analyses in large
Cherenkov detectors, particularly those that involve separating
extraterrestrial neutrinos from the atmospheric neutrino background. Muon
energy has traditionally been determined by measuring the specific energy loss
(dE/dx) along the muon's path and relating the dE/dx to the muon energy.
Because high-energy muons (E_mu > 1 TeV) lose energy randomly, the spread in
dE/dx values is quite large, leading to a typical energy resolution of 0.29 in
log10(E_mu) for a muon observed over a 1 km path length in the IceCube
detector. In this paper, we present an improved method that uses a truncated
mean and other techniques to determine the muon energy. The muon track is
divided into separate segments with individual dE/dx values. The elimination of
segments with the highest dE/dx results in an overall dE/dx that is more
closely correlated to the muon energy. This method results in an energy
resolution of 0.22 in log10(E_mu), which gives a 26% improvement. This
technique is applicable to any large water or ice detector and potentially to
large scintillator or liquid argon detectors.Comment: 12 pages, 16 figure
The Cosmological Slingshot Scenario: Myths and Facts
We generalize the Cosmological Slingshot Scenario for a Slingshot brane
moving in a Klebanov-Strassler throat. We show that the horizon and isotropy
problems of standard cosmology are avoided, while the flatness problem is
acceptably alleviated. Regarding the primordial perturbations, we identify
their vacuum state and elucidate the evolution from the quantum to the
classical regimes. Also, we calculate their exact power spectrum showing its
compatibility with current data. We discuss the bouncing solution from a four
dimensional point of view. In this framework the radial and angular motion of
the Slingshot brane are described by two scalar fields. We show that the
bouncing solution for the scale factor in String frame is mapped into a
monotonically increasing (in conformal time) solution in the Einstein frame. We
finally discuss about the regularity of the geometry in Einstein frame.Comment: 16 pages, 2 figs. Major clarifications and references added, version
accepted in Gen. Rel. Grav. (2009
Neutrino oscillation studies with IceCube-DeepCore
AbstractIceCube, a gigaton-scale neutrino detector located at the South Pole, was primarily designed to search for astrophysical neutrinos with energies of PeV and higher. This goal has been achieved with the detection of the highest energy neutrinos to date. At the other end of the energy spectrum, the DeepCore extension lowers the energy threshold of the detector to approximately 10 GeV and opens the door for oscillation studies using atmospheric neutrinos. An analysis of the disappearance of these neutrinos has been completed, with the results produced being complementary with dedicated oscillation experiments. Following a review of the detector principle and performance, the method used to make these calculations, as well as the results, is detailed. Finally, the future prospects of IceCube-DeepCore and the next generation of neutrino experiments at the South Pole (IceCube-Gen2, specifically the PINGU sub-detector) are briefly discussed
Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19
BACKGROUND REGEN-COV (previously known as REGN-COV2), a combination of the monoclonal antibodies casirivimab and imdevimab, has been shown to markedly reduce the risk of hospitalization or death among high-risk persons with coronavirus disease 2019 (Covid-19). Whether subcutaneous REGEN-COV prevents severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and subsequent Covid-19 in persons at high risk for infection because of household exposure to a person with SARS-CoV-2 infection is unknown. METHODS We randomly assigned, in a 1:1 ratio, participants (=12 years of age) who were enrolled within 96 hours after a household contact received a diagnosis of SARSCoV- 2 infection to receive a total dose of 1200 mg of REGEN-COV or matching placebo administered by means of subcutaneous injection. At the time of randomization, participants were stratified according to the results of the local diagnostic assay for SARS-CoV-2 and according to age. The primary efficacy end point was the development of symptomatic SARS-CoV-2 infection through day 28 in participants who did not have SARS-CoV-2 infection (as measured by reverse-transcriptase- quantitative polymerase-chain-reaction assay) or previous immunity (seronegativity). RESULTS Symptomatic SARS-CoV-2 infection developed in 11 of 753 participants in the REGEN-COV group (1.5%) and in 59 of 752 participants in the placebo group (7.8%) (relative risk reduction [1 minus the relative risk], 81.4%; P104 copies per milliliter) was shorter (0.4 weeks and 1.3 weeks, respectively). No dose-limiting toxic effects of REGEN-COV were noted. CONCLUSIONS Subcutaneous REGEN-COV prevented symptomatic Covid-19 and asymptomatic SARS-CoV-2 infection in previously uninfected household contacts of infected persons. Among the participants who became infected, REGEN-COV reduced the duration of symptomatic disease and the duration of a high viral load
Recommended from our members
Track A Basic Science
Peer Reviewedhttps://deepblue.lib.umich.edu/bitstream/2027.42/138319/1/jia218438.pd
Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Background:
In this study, we aimed to evaluate the effects of tocilizumab in adult patients admitted to hospital with COVID-19 with both hypoxia and systemic inflammation.
Methods:
This randomised, controlled, open-label, platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), is assessing several possible treatments in patients hospitalised with COVID-19 in the UK. Those trial participants with hypoxia (oxygen saturation <92% on air or requiring oxygen therapy) and evidence of systemic inflammation (C-reactive protein ≥75 mg/L) were eligible for random assignment in a 1:1 ratio to usual standard of care alone versus usual standard of care plus tocilizumab at a dose of 400 mg–800 mg (depending on weight) given intravenously. A second dose could be given 12–24 h later if the patient's condition had not improved. The primary outcome was 28-day mortality, assessed in the intention-to-treat population. The trial is registered with ISRCTN (50189673) and ClinicalTrials.gov (NCT04381936).
Findings:
Between April 23, 2020, and Jan 24, 2021, 4116 adults of 21 550 patients enrolled into the RECOVERY trial were included in the assessment of tocilizumab, including 3385 (82%) patients receiving systemic corticosteroids. Overall, 621 (31%) of the 2022 patients allocated tocilizumab and 729 (35%) of the 2094 patients allocated to usual care died within 28 days (rate ratio 0·85; 95% CI 0·76–0·94; p=0·0028). Consistent results were seen in all prespecified subgroups of patients, including those receiving systemic corticosteroids. Patients allocated to tocilizumab were more likely to be discharged from hospital within 28 days (57% vs 50%; rate ratio 1·22; 1·12–1·33; p<0·0001). Among those not receiving invasive mechanical ventilation at baseline, patients allocated tocilizumab were less likely to reach the composite endpoint of invasive mechanical ventilation or death (35% vs 42%; risk ratio 0·84; 95% CI 0·77–0·92; p<0·0001).
Interpretation:
In hospitalised COVID-19 patients with hypoxia and systemic inflammation, tocilizumab improved survival and other clinical outcomes. These benefits were seen regardless of the amount of respiratory support and were additional to the benefits of systemic corticosteroids.
Funding:
UK Research and Innovation (Medical Research Council) and National Institute of Health Research
Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial
Background:
Many patients with COVID-19 have been treated with plasma containing anti-SARS-CoV-2 antibodies. We aimed to evaluate the safety and efficacy of convalescent plasma therapy in patients admitted to hospital with COVID-19.
Methods:
This randomised, controlled, open-label, platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]) is assessing several possible treatments in patients hospitalised with COVID-19 in the UK. The trial is underway at 177 NHS hospitals from across the UK. Eligible and consenting patients were randomly assigned (1:1) to receive either usual care alone (usual care group) or usual care plus high-titre convalescent plasma (convalescent plasma group). The primary outcome was 28-day mortality, analysed on an intention-to-treat basis. The trial is registered with ISRCTN, 50189673, and ClinicalTrials.gov, NCT04381936.
Findings:
Between May 28, 2020, and Jan 15, 2021, 11558 (71%) of 16287 patients enrolled in RECOVERY were eligible to receive convalescent plasma and were assigned to either the convalescent plasma group or the usual care group. There was no significant difference in 28-day mortality between the two groups: 1399 (24%) of 5795 patients in the convalescent plasma group and 1408 (24%) of 5763 patients in the usual care group died within 28 days (rate ratio 1·00, 95% CI 0·93–1·07; p=0·95). The 28-day mortality rate ratio was similar in all prespecified subgroups of patients, including in those patients without detectable SARS-CoV-2 antibodies at randomisation. Allocation to convalescent plasma had no significant effect on the proportion of patients discharged from hospital within 28 days (3832 [66%] patients in the convalescent plasma group vs 3822 [66%] patients in the usual care group; rate ratio 0·99, 95% CI 0·94–1·03; p=0·57). Among those not on invasive mechanical ventilation at randomisation, there was no significant difference in the proportion of patients meeting the composite endpoint of progression to invasive mechanical ventilation or death (1568 [29%] of 5493 patients in the convalescent plasma group vs 1568 [29%] of 5448 patients in the usual care group; rate ratio 0·99, 95% CI 0·93–1·05; p=0·79).
Interpretation:
In patients hospitalised with COVID-19, high-titre convalescent plasma did not improve survival or other prespecified clinical outcomes.
Funding:
UK Research and Innovation (Medical Research Council) and National Institute of Health Research
- …